Forward Pharma (FWP)

Overall impact
B (70)

Commentary

Forward Pharma is a strong overall performer. With a 'B' rating of 69.6 for overall impact (81st percentile compared to all companies), Forward Pharma ranks 282nd out of 585 industry peers, behind Biogen, Gilead Sciences, Amgen and 278 others, and ahead of Grifols, Ionis Pharmaceuticals, Jazz Pharmaceuticals and 300 others. On top material causes for Forward Pharma's industry (Pharmaceuticals & Biotech), Forward Pharma performs well in Child and Maternal Health (87.9 score), Reduced Use of tobacco (80.5), Child and Maternal Health (95.0) and 4 other causes where it received an 'A' score and performs poorly in Accountable Institutions (20.1 score) and Reduced Green House Gas Emissions (35.7).
Impact
Cause FWP
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2005
Employees
4
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Denmark
Share classes
FWPAD
ADR
FWP
Description
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187, a proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
Material causes
Ethos considers the following causes material for Forward Pharma, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.